N
Nicholas Zdenkowski
Researcher at University of Newcastle
Publications - 53
Citations - 717
Nicholas Zdenkowski is an academic researcher from University of Newcastle. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 12, co-authored 41 publications receiving 432 citations. Previous affiliations of Nicholas Zdenkowski include Mater Health Services & Newcastle University.
Papers
More filters
Journal ArticleDOI
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Erica L. Mayer,Amylou C. Dueck,Miguel Martín,G. Rubovszky,Harold J. Burstein,Meritxell Bellet-Ezquerra,Kathy D. Miller,Nicholas Zdenkowski,Eric P. Winer,Georg Pfeiler,Matthew Bidwell Goetz,Manuel Ruiz-Borrego,Daniel G. Anderson,Zbigniew Nowecki,Sibylle Loibl,Stacy L. Moulder,Alistair Ring,Florian Fitzal,Tiffany A. Traina,Arlene Chan,Hope S. Rugo,Julie Lemieux,Fernando Henao,Alan P. Lyss,Silvia Antolin Novoa,Antonio C. Wolff,Marcus Vetter,Daniel Egle,Patrick G. Morris,Eleftherios P. Mamounas,Miguel Gil-Gil,Aleix Prat,Hannes Fohler,Otto Metzger Filho,Magdalena Schwarz,Carter Dufrane,Debora Fumagalli,Kathy Puyana Theall,D. Lu,Cynthia Huang Bartlett,Maria Koehler,Christian Fesl,Angela DeMichele,Michael Gnant +43 more
TL;DR: The PALLAS trial as discussed by the authors investigated whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine treatment alone in patients with hormone-receptor-positive, HER2-negative, early stage breast cancer.
Journal ArticleDOI
A systematic review of decision aids for patients making a decision about treatment for early breast cancer.
TL;DR: Summary: Decision aids are available and improved decision-related outcomes for many breast cancer treatment decisions including surgery, radiotherapy, and endocrine and chemotherapy, including neoadjuvant systemic therapy and contralateral prophylactic mastectomy can be found.
Journal ArticleDOI
What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta‐analysis
Yvonne L Luigjes-Huizer,Nina M Tauber,Gerry Humphris,Nadine A. Kasparian,Wendy W. T. Lam,Sophie Lebel,Sébastien Simard,Allan Ben Smith,Robert Zachariae,Yati Afiyanti,Katy J.L. Bell,José A. E. Custers,Niek J. de Wit,Peter L Fisher,Jacqueline Galica,Sheila N. Garland,Charles W Helsper,Mette Moustgaard Jeppesen,Jianxin Liu,Roxana Mititelu,Evelyn M. Monninkhof,Lahiru Russell,Josée Savard,Anne E. M. Speckens,Sanne Jasperine van Helmondt,Sina Vatandoust,Nicholas Zdenkowski,Marije L van der Lee +27 more
TL;DR: A comprehensive overview of the prevalence and severity of FCR among cancer survivors and patients, as measured using the short form of the validated Fear of Cancer Recurrence Inventory (FCRI‐SF).
Journal ArticleDOI
Administration of chemotherapy with palliative intent in the last 30 days of life: The balance between palliation and chemotherapy
TL;DR: There is wide variation in the reported rates of chemotherapy administration within the last 30 days of life.
Journal ArticleDOI
Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options
Janine M. Lombard,Nicholas Zdenkowski,Kathy Wells,Corinna Beckmore,Linda Reaby,John F. Forbes,Jacquie Chirgwin +6 more
TL;DR: It is concluded that aromatase inhibitor induced musculoskeletal syndrome is a significant issue for Australian women and is an important reason for treatment discontinuation.